Tumor Biology

, Volume 37, Issue 6, pp 7881–7891 | Cite as

Contributions of phosphatidylserine-positive platelets and leukocytes and microparticles to hypercoagulable state in gastric cancer patients

  • Chunfa Yang
  • Ruishuang Ma
  • Tao Jiang
  • Muhua Cao
  • Liangliang Zhao
  • Yayan Bi
  • Junjie Kou
  • Jialan ShiEmail author
  • Xiaoming ZouEmail author
Original Article


Hypercoagulability in gastric cancer is a common complication and a major contributor to poor prognosis. This study aimed to determine procoagulant activity of blood cells and microparticles (MPs) in gastric cancer patients. Phosphatidylserine-positive blood cells and MPs, and their procoagulant properties in particular, were assessed in 48 gastric cancer patients and 35 healthy controls. Phosphatidylserine-positive platelets, leukocytes, and MPs in patients with tumor-node-metastasis stage III/IV gastric cancer were significantly higher than those in stage I/II patients or healthy controls. Moreover, procoagulant activity of platelets, leukocytes, and MPs in stage III/IV patients was significantly increased compared to the controls, as indicated by shorter clotting time, higher intrinsic and extrinsic factor tenase, and prothrombinase complex activity. Interestingly, lactadherin, which competes with factors V and VIII to bind phosphatidylserine, dramatically prolonged clotting time of the cells and MPs by inhibiting factor tenase and prothrombinase complex activity. Although anti-tissue factor antibody significantly attenuated extrinsic tenase complex activity of leukocytes and MPs, it only slightly prolonged clotting times. Meanwhile, treatment with radical resection reduced phosphatidylserine-positive platelets, leukocytes, and MPs, and prolonged the clotting times of the remaining cells and MPs. Our results suggest that phosphatidylserine-positive platelets, leukocytes, and MPs contribute to hypercoagulability and represent a potential therapeutic target to prevent coagulation in patients with stage III/IV gastric cancer.


Gastric cancer Prothrombotic state Phosphatidylserine Tissue factor Microparticles 









Tissue factor


Procoagulant activity



We thank Xingku Li and Yan Xia for the excellent technical assistance. This work was supported by the National Natural Science Foundation of China (81270588, 81470301) and Graduate Innovation Fund of Harbin Medical University (YJSCX2014-02HYD).

Authorship contributions

Chunfa Yang, Xiaoming Zou, and Jialan Shi contributed to the research design, conducting of the experiments, data analysis, and writing of the paper. Ruishang Ma, Tao Jiang, Muhua Cao, Liangliang Zhao, Junjie Kou, and Yayan Bi contributed to the experimental design, analysis of data, and revision of the manuscript.

Compliance with ethical standards

The study was approved by Ethics Committee of Harbin Medical University in accordance with the Declaration of Helsinki.

Conflicts of interest



  1. 1.
    Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost. 2010;8:540–7.CrossRefPubMedGoogle Scholar
  3. 3.
    White RH, Chew H, Wun T. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? Thromb Res. 2007;120 Suppl 2:S29–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Di Micco P, Romano M, Niglio A, et al. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis. 2001;33:546–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Fidan E, Kavgaci H, Orem A, et al. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer. Tumor Biol. 2012;33:1519–25.CrossRefGoogle Scholar
  6. 6.
    Kwon HC, Oh SY, Lee S, et al. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006;10:355–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Boccaccio C, Comoglio PM. Genetic link between cancer and thrombosis. J Clin Oncol. 2009;27:4827–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA. 2012;109:13076–81.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shao B, Wahrenbrock MG, Yao L, et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 2011;118:4015–23.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–62.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res. 2005;44:207–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Delaney MK, Liu J, Kim K, et al. Agonist-induced platelet procoagulant activity requires shear and a Rac1-dependent signaling mechanism. Blood. 2014;124:1957–67.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wahid ST, Marshall SM, Thomas TH. Increased platelet and erythrocyte external cell membrane phosphatidylserine in type 1 diabetes and microalbuminuria. Diabetes Care. 2001;24:2001–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Gao C, Xie R, Yu C, et al. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb Haemost. 2012;107:681–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Tan X, Shi J, Fu Y, et al. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation. Thromb Haemost. 2013;109:1025–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Baran J, Baj-Krzyworzeka M, Weglarczyk K, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010;59:841–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim HK, Song KS, Park YS, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184–91.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamashita H, Kitayama J, Ishikawa M, et al. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. J Surg Oncol. 2007;95:324–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Lo L, Valentine H, Harrison J, et al. Tissue factor expression in the metaplasia-adenoma-carcinoma sequence of gastric cancer in a European population. Br J Cancer. 2012;107:1125–30.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hernandez C, Orbe J, Roncal C, et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost. 2013;110:598–608.CrossRefPubMedGoogle Scholar
  22. 22.
    Shi J, Gilbert GE. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. Blood. 2003;101:2628–36.CrossRefPubMedGoogle Scholar
  23. 23.
    Shi J, Heegaard CW, Rasmussen JT, et al. Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature. Biochim Biophys Acta. 2004;1667:82–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Gao C, Xie R, Li W, et al. Endothelial cell phagocytosis of senescent neutrophils decreases procoagulant activity. Thromb Haemost. 2013;109:1079–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhou J, Liu S, Ma M, et al. Procoagulant activity and phosphatidylserine of amniotic fluid cells. Thromb Haemost. 2009;101:845–51.PubMedGoogle Scholar
  26. 26.
    Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost. 2009;7:190–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Aleman MM, Gardiner C, Harrison P, et al. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost. 2011;9:2251–61.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Sarlon-Bartoli G, Bennis Y, Lacroix R, et al. Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. J Am Coll Cardiol. 2013;62:1436–41.CrossRefPubMedGoogle Scholar
  29. 29.
    Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012;33:1469–79.CrossRefPubMedGoogle Scholar
  30. 30.
    Augustine D, Ayers LV, Lima E, et al. Dynamic release and clearance of circulating microparticles during cardiac stress. Circ Res. 2014;114:109–13.CrossRefPubMedGoogle Scholar
  31. 31.
    van Doormaal F, Kleinjan A, Berckmans RJ, et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost. 2012;108:160–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Laresche C, Pelletier F, Garnache-Ottou F, et al. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol. 2014;134:176–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Toth B, Liebhardt S, Steinig K, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008;100:663–9.PubMedGoogle Scholar
  34. 34.
    Thaler J, Koder S, Kornek G, et al. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res. 2014;163:145–50.CrossRefPubMedGoogle Scholar
  35. 35.
    Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2012;30:3870–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Hong SK, Ko DW, Park J, et al. Alteration of antithrombin III and D-dimer levels in clinically localized prostate cancer. Korean J Urol. 2010;51:25–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Xu G, Zhang YL, Huang W. Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J Gastroenterol. 2004;10:922–3.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Byrne M, Reynolds JV, O’Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer. 2010;102:73–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Jeong O, Ryu SY, Park YK, et al. The effect of low molecular weight heparin thromboprophylaxis on bleeding complications after gastric cancer surgery. Ann Surg Oncol. 2010;17:2363–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Mita K, Ito H, Murabayashi R, et al. Postoperative bleeding complications after gastric cancer surgery in patients receiving anticoagulation and/or antiplatelet agents. Ann Surg Oncol. 2012;19:3745–52.CrossRefPubMedGoogle Scholar
  42. 42.
    Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. Thromb Res. 2012;129:568–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Akl EA, Schünemann HJ. Routine heparin for patients with cancer? One answer, more questions. N Engl J Med. 2012;366:661–2.CrossRefPubMedGoogle Scholar
  46. 46.
    Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Chunfa Yang
    • 1
  • Ruishuang Ma
    • 2
  • Tao Jiang
    • 3
  • Muhua Cao
    • 2
  • Liangliang Zhao
    • 3
  • Yayan Bi
    • 2
  • Junjie Kou
    • 4
  • Jialan Shi
    • 2
    • 5
    Email author
  • Xiaoming Zou
    • 1
    Email author
  1. 1.Department of Gastrointestinal SurgeryThe Second Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Department of MedicineThe First Hospital of Harbin Medical UniversityHarbinChina
  3. 3.Department of Gastrointestinal SurgeryThe First Hospital of Harbin Medical UniversityHarbinChina
  4. 4.Department of CardiologyThe Second Hospital of Harbin Medical UniversityHarbinChina
  5. 5.Department of HematologyThe First Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations